Thyroid Cancer Outcomes at KFSYSCC

Between 2013-2017, the five-year survival rate for prostate cancer at KFSYSCC was 98% vs 94% for other hospitals in Taiwan.

Basic Information and Distribution of 1,919 Thyroid Cancer Patients at KFSYSCC from 1990-2019

  
    


    
    
    




    
            
            Total
            1990-1994
            1995-1999
            2000-2004
            2005-2009
            2010-2014
            2015-2019
        

    
            n
            1,919
            21 (1%)
            113 (6%)
            322 (17%)
            419 (22%)
            557 (29%)
            487 (25%)
        

            Gender (%)
        

            Male
            438 (23%)
            5 (24%)
            22 (20%)
            71 (22%)
            88 (21%)
            120 (22%)
            132 (27%)
        

            Female
            1,481 (77%)
            16 (76%)
            91 (80%)
            251 (78%)
            331 (79%)
            437 (78%)
            355 (73%)
        

            Age
        

            Mean/Median
            45/44
            45/41
            46/42
            43/42
            43/42
            45/45
            47/47
        

            Range
            7-94
            14-83
            19-94
            16-90
            13-84
            7-86
            15-82
        

            Q1-Q3
            36-54
            31-60
            34-59
            33-51
            33-52
            36-53
            39-56
        

            Stage (%)
        

            I
            1,134 (59%)
            8 (38%)
            27 (24%)
            131 (41%)
            261 (62%)
            360 (65%)
            347 (71%)
        

            II
            189 (10%)
            6 (29%)
            21 (19%)
            64 (20%)
            36 (9%)
            33 (6%)
            29 (6%)
        

            III
            294 (15%)
            0 (0%)
            5 (4%)
            54 (17%)
            58 (14%)
            117 (21%)
            60 (12%)
        

            IV
            146 (8%)
            1 (5%)
            4 (4%)
            20 (6%)
            39 (9%)
            37 (7%)
            45 (9%)
        

            Unknown
            156 (8%)
            6 (29%)
            56 (50%)
            53 (16%)
            25 (6%)
            10 (2%)
            6 (1%)
        






  

	Total	1990-1994	1995-1999	2000-2004	2005-2009	2010-2014	2015-2019
n	1,919	21 (1%)	113 (6%)	322 (17%)	419 (22%)	557 (29%)	487 (25%)
Gender (%)
Male	438 (23%)	5 (24%)	22 (20%)	71 (22%)	88 (21%)	120 (22%)	132 (27%)
Female	1,481 (77%)	16 (76%)	91 (80%)	251 (78%)	331 (79%)	437 (78%)	355 (73%)
Age
Mean/Median	45/44	45/41	46/42	43/42	43/42	45/45	47/47
Range	7-94	14-83	19-94	16-90	13-84	7-86	15-82
Q1-Q3	36-54	31-60	34-59	33-51	33-52	36-53	39-56
Stage (%)
I	1,134 (59%)	8 (38%)	27 (24%)	131 (41%)	261 (62%)	360 (65%)	347 (71%)
II	189 (10%)	6 (29%)	21 (19%)	64 (20%)	36 (9%)	33 (6%)	29 (6%)
III	294 (15%)	0 (0%)	5 (4%)	54 (17%)	58 (14%)	117 (21%)	60 (12%)
IV	146 (8%)	1 (5%)	4 (4%)	20 (6%)	39 (9%)	37 (7%)	45 (9%)
Unknown	156 (8%)	6 (29%)	56 (50%)	53 (16%)	25 (6%)	10 (2%)	6 (1%)

Based on KFSYSCC's cancer registry data from 1990 to 2019, there were a total of 1,919 analytic thyroid cancer cases, comprising 438 males (23%) and 1,481 females (77%). The average and median ages were 45 and 44 years old, respectively, with the youngest patient at 7 and the oldest at 94 years old; the interquartile range (Q1-Q3) spanned 36-54 years. When examined by stage, 1,134 patients were stage I (59%), 189 were stage II (10%), 294 were stage III (15%), and 146 were stage IV (8%). The table below presents the basic patient information and stage distribution, categorized by the year of diagnosis.

Survival curves for 1,919 thyroid cancer patients diagnosed between 1990 and 2019, stratified by year of diagnosis, showing overall survival probability over years after diagnosis.

Survival Curves for 1,919 Thyroid Cancer Patients (1990-2019), Stratified by Year of Diagnosis

From 1990 to 2019, the chart illustrates the five-year observed survival rates for 1,919 thyroid cancer patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for thyroid cancer increased from 90% in 1990-1994 to 97% in 2015-2019, while the ten-year survival rate rose from 85% in 1990-1994 to 97% in 2010-2014.

Treatment Methods and Stages for 487 Thyroid Cancer Patients at KFSYSCC (2015-2019)

  
    


    
    
    


    
    
        
            Treatment Type
            Total
            Stage I
            Stage II
            Stage III
            Stage IV
            Unknown
        

            Total
            487
            347
            29
            60
            45
            6
        

            Surgical Treatment
            483 (99%)
            347 (100%)
            29 (100%)
            60 (100%)
            41 (91%)
            6 (100%)
        

            Radiation Therapy
            301 (62%)
            179 (52%)
            23 (79%)
            55 (92%)
            41 (91%)
            3 (50%)
        

            Chemotherapy
            4 (1%)
            0 (0%)
            0 (0%)
            0 (0%)
            3 (7%)
            1 (17%)
        

            Targeted Therapy
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
        

            Hormone Therapy
            355 (73%)
            233 (67%)
            23 (79%)
            55 (92%)
            39 (87%)
            5 (83%)
        

            Immunotherapy
            1 (0.2%)
            1 (0.3%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
        

            Palliative Care
            5 (1%)
            2 (1%)
            1 (3%)
            0 (0%)
            2 (4%)
            0 (0%)
        

            Bone Marrow/Stem Cell Transplant
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
        

            No Record of Initial Treatment Reported
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
            0 (0%)
        





  

Treatment Type	Total	Stage I	Stage II	Stage III	Stage IV	Unknown
Total	487	347	29	60	45	6
Surgical Treatment	483 (99%)	347 (100%)	29 (100%)	60 (100%)	41 (91%)	6 (100%)
Radiation Therapy	301 (62%)	179 (52%)	23 (79%)	55 (92%)	41 (91%)	3 (50%)
Chemotherapy	4 (1%)	0 (0%)	0 (0%)	0 (0%)	3 (7%)	1 (17%)
Targeted Therapy	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Hormone Therapy	355 (73%)	233 (67%)	23 (79%)	55 (92%)	39 (87%)	5 (83%)
Immunotherapy	1 (0.2%)	1 (0.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Palliative Care	5 (1%)	2 (1%)	1 (3%)	0 (0%)	2 (4%)	0 (0%)
Bone Marrow/Stem Cell Transplant	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
No Record of Initial Treatment Reported	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Between 2015 and 2019, there were a total of 487 analytic thyroid cancer cases, including 347 patients in stage I, 29 in stage II, 60 in stage III, and 45 in stage IV. In terms of treatment methods, 483 patients (99%) underwent surgical treatment, 301 (62%) received radiation therapy, 4 (1%) underwent chemotherapy, 355 (73%) received hormone therapy, 1 (0.2%) underwent immunotherapy, and 5 (1%) received palliative care.

Line graph showing five-year survival rates of 487 thyroid cancer patients by stage from 2015 to 2019. The y-axis represents the probability of overall survival, and the x-axis shows years after diagnosis. The graph includes data for stages I, II, III, IV, and unknown, with survival rates starting at 100%, 97%, 100%, and 74%, respectively, and remaining high over five years.

Five-Year Survival Rates of 487 Thyroid Cancer Patients by Stage (2015-2019)

KFSYSCC’s 2015-2019 five-year observed survival rates for 487 thyroid cancer patients, stratified by stage, are presented in the following chart. As shown in the graph, the five-year survival rate is 100% for stage 1, 97% for stage 2, 100% for stage 3, and 74% for stage 4.